Aptorum Group

APM

Market cap $14.1M

Overview Fund Activity

1.98 USD

+0.13

7.03%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.92

-0.06

3.03%

1 day

7.03%

5 days

10%

1 month

42.45%

3 months

67.8%

6 months

112.93%

Year to date

-10%

1 year

-27.74%

5 years

-88.07%

10 years

-98.62%

About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Employees: 1

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

1.04% less ownership

Funds ownership: 1.76% [Q1] → 0.72% (-1.04%) [Q2]

56% less capital invested

Capital invested by funds: $79.2K [Q1] → $35K (-$44.2K) [Q2]

63% less funds holding

Funds holding: 8 [Q1] → 3 (-5) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

See Fund Rankings

Financial journalist opinion

Based on 3 articles about APM published over the past 30 days

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconference/).

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

Aptorum shares trade higher on 168.16 million volume vs 3.25 million average. DiamiR gains CLEP approval for APOE Genotyping test in New York.

Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript

Andean Precious Metals Corp. (OTCQX:ANPMF) Q2 2025 Earnings Conference Call August 13, 2025 9:00 AM ET Company Participants Alberto Morales - Founder, CEO & Executive Chairman Amanda Mallough - Corporate Participant Dom Kizek - Corporate Participant Juan Carlos Sandoval - Chief Financial Officer Yohann Bouchard - President & Director Conference Call Participants Allison Carson - Desjardins Securities Inc., Research Division Ben Pirie - Atrium Research Corporation Justin Chan - SCP Resource Finance LP, Research Division Operator Good morning, and welcome to Andean Precious Metals Second Quarter 2025 Results Conference Call. As a remainder, all participants are in the listen-only-mode.

Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bid price requirement.

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

BELLEVUE, Wash.--(BUSINESS WIRE)--Synology launches the ActiveProtect series a unified enterprise backup solution set to disrupt the current data backup market.

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share.

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. “Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary tra.

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

See News Rankings

Charts implemented using Lightweight Charts™